CHRS: coherus.com Amount of Cash per Share

Corporate emblem and logo of Coherus BioSciences, Inc (CHRS)

The oncology drug market is currently expanding rapidly, allowing Coherus Biosciences (CHRS) to grow its customer base through new immunotherapies. This enables the company to pivot from biosimilars toward its own proprietary antibodies to combat pricing pressure. Marketing and production efficiency is maintained by leveraging external logistics partners. Cash per share trends visualize liquidity, where the value of 0.55 captures the metric level.

CHRS: Coherus BioSciences Cash per Share 07/04/2022 - 11/20/2026

Analytical breakdowns for Coherus Biosciences

- market price and analyst price targets:
- cash position and cash flow details:
Summary company analysis:CHRS, Coherus BioSciences Inc.
Original product of Coherus BioSciences, Inc

Coherus Biosciences (CHRS) is currently undergoing a rigorous transformation, shifting its focus from biosimilars to the development of its own immuno-oncology platform to return to profitability. This metric measures the volume of liquid assets per share, allowing the cash per share data on GURU.Markets to determine whether the decline in share price is outpacing the actual reduction of capital during this period of business restructuring.